Consulting Services
For Investors
- Lucid Diligence Briefs
- Venture Capital Trends
Case Studies
Insights
- Conference Previews
- Conference Social Media Reports
LucidWargames
QuickAnswers
LucidSearch
BioPharma and Tech News

Contact Us

Search

EULAR

Immunology

Immunology Today—December 17, 2025

This week in immunology: the latest clinical updates, industry progress, and…

Immunology

Immunology Video Recap—December 3, 2025

This biweekly immunology video highlights major regulatory wins, evolving…

Categories

Obesity News
Endocrinology News
Our Insights
Immunology News
Case studies
Hematology News
BioPharma and Tech News
Oncology News
BioPharma Strategy, CI and AI Guides
Lucid Diligence Brief
Conference Social Media Reports
Venture Capital Trends
AI in Healthcare and Digital Health
Conference Previews
Cell and Gene Therapy News
Rare Disease News
Neuroscience News
Women's Health News
Public Health News
Respiratory News
Cardiovascular News
Vaccine news

Recent Posts

Lucid Diligence Brief: PAQ Therapeutics Series B for PT0511 pan-KRAS degrader
AI in Healthcare and Digital Health Today—January 26, 2026
Lucid Diligence Brief: CORXEL $287m Series D1 for oral GLP-1 development
Lucid Diligence Brief: Mendra $82 million Series A to support AI-enabled rare-disease therapeutics
Respiratory Video Recap—January 23, 2026

Tags

AB Science adolescent smartphone exposure arrhythmias B-cell architecture analysis Bluejay Therapeutics Canada National Strategy for Drugs for Rare Diseases cancer Celea Therapeutics clinical validation Congenital disorder of glycosylation CorEvitas Coronary artery calcium depemokimab Drug Development Innovation Elranatamab enterprise AI Fruzaqla Global obesity market HBICE Hematologic malignancies hematology HSA Huons INHALE 1 study ivc thrombectomy LUMC mavacamten Medical Care Technologies metastatic uveal melanoma Monoclonal antibodies Myocarditis neuroinflammatory diseases NIHR Southampton non viral vectors pharma Pluristyx Prurigo nodularis Relutrigine rosacea Rubraca Sema4 Stem-cell diabetes therapy T-cell engager Tessera Therapeutics Zika vaccine

Archives

Archives

LucidQuest Ventures

Accelerate Your Success

LATEST NEWS

Lucid Diligence Brief: PAQ Therapeutics Series B for PT0511 pan-KRAS degrader
AI in Healthcare and Digital Health Today—January 26, 2026
Lucid Diligence Brief: CORXEL $287m Series D1 for oral GLP-1 development
Lucid Diligence Brief: Mendra $82 million Series A to support AI-enabled rare-disease therapeutics
Respiratory Video Recap—January 23, 2026

TAGS

AB Science adolescent smartphone exposure arrhythmias B-cell architecture analysis Bluejay Therapeutics Canada National Strategy for Drugs for Rare Diseases cancer Celea Therapeutics clinical validation Congenital disorder of glycosylation CorEvitas Coronary artery calcium depemokimab Drug Development Innovation Elranatamab enterprise AI Fruzaqla Global obesity market HBICE Hematologic malignancies hematology HSA Huons INHALE 1 study ivc thrombectomy LUMC mavacamten Medical Care Technologies metastatic uveal melanoma Monoclonal antibodies Myocarditis neuroinflammatory diseases NIHR Southampton non viral vectors pharma Pluristyx Prurigo nodularis Relutrigine rosacea Rubraca Sema4 Stem-cell diabetes therapy T-cell engager Tessera Therapeutics Zika vaccine

Consulting Services
For Investors
- Lucid Diligence Briefs
- Venture Capital Trends
Case Studies
Insights
- Conference Previews
- Conference Social Media Reports
LucidWargames
QuickAnswers
LucidSearch
BioPharma and Tech News

© 2026 LucidQuest Ventures. All rights reserved

We use cookies from third party services to offer you a better experience. Read about how we use cookies and how you can control them by clicking "Privacy Preferences".

Privacy Preference Center

Privacy Preferences

When you visit any website, it may store or retrieve information on your browser in the form of cookies. Since we respect your right to privacy, you can choose not to permit data collection from certain types of services. However, not allowing these services may impact your experience ans we are able to offer you.

Privacy Policy

Required

You read and agreed to our Privacy Policy

Tracking

We use third-party cookies that help us analyze and understand how you use this website. These cookies do not store any personal information.

Privacy Policy